Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03296371 · ClinicalTrials.gov registry record
Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma
A clinical trial of Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma, sponsored by Children's Oncology Group.
- Active
- Registry status
- 900
- Enrollment target
- 1
- Study location
NCT03296371 is a study of Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 900 participants, above the 216-participant average among 3 other Embryonal Rhabdomyosarcoma trials with a reported enrollment target (317% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03296371, a study of Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 1
- Study location
Study Summary
This research trial studies genetic mutations in saliva or buccal mucosa samples from patients with embryonal or alveolar rhabdomyosarcoma. Identifying gene mutations may help doctors learn about the prognosis of patients with embryonal or alveolar rhabdomyosarcoma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
Study Locations (1)
Pennsylvania
- Childrens Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03296371
The ClinicalTrials.gov registry entry for NCT03296371 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 216-participant average among 3 other Embryonal Rhabdomyosarcoma trials with a reported enrollment target (317% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Embryonal Rhabdomyosarcoma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT03296371 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03296371 about?
NCT03296371 is a clinical study titled "Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma". This research trial studies genetic mutations in saliva or buccal mucosa samples from patients with embryonal or alveolar rhabdomyosarcoma. Identifying gene mutations may help doctors learn about the prognosis of patients with embryonal or alveolar rhabdomyosarcoma.
What is the current status of trial NCT03296371?
This trial is currently active not recruiting. The enrollment target is 900 participants. The study started on 2017-10-23. Estimated completion is 2026-12-31.
What conditions does trial NCT03296371 study?
This clinical trial studies the following conditions: Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma.
What interventions are being tested in trial NCT03296371?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT03296371?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03296371 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Embryonal Rhabdomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
RECRUITING · Phase 3
-
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.